Rifaximin versus chlortetracycline in the short‐term treatment of small intestinal bacterial overgrowth
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: Bacterial overgrowth of the small intestine is a condition characterized by nutrient malabsorption due to an excessive number of bacteria in the lumen of the small intestine. Current treatment is based on empirical courses of broad spectrum antibiotics; few controlled data, with respect to the duration and choice of antibiotic drug, exist at present. The recent availability of rifaximin, a non‐absorbable rifamycin derivative, highly effective against anaerobic bacteria, prompted us to carry out a randomized, double‐blind controlled trial in order to compare its efficacy and tolerability to those of tetracycline, currently considered the first‐choice drug. Methods: In 21 patients affected by small intestinal bacterial overgrowth, fasting, peak and total H 2 excretion after ingestion of 50 g glucose and severity of symptoms were evaluated before and after a 7‐day course of rifaximin, 1200 mg/day (400 mg t.d.s.), or chlortetracycline, 1 g/day (333 mg␣t.d.s.). Results: Fasting, peak and total H 2 excretion decreased significantly in the group of patients treated with rifaximin whereas chlortetracycline did not modify these parameters. The H 2 breath test normalized in 70% of patients after rifaximin and in 27% of patients after chlortetracycline. The improvement in symptoms was significantly higher in patients treated with rifaximin. Conclusions: Rifaximin is a promising, easily‐handled and safe drug for the short‐term treatment of small intestinal bacterial overgrowth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fasting breath hydrogen in celiac disease
Corazza, G. R., Strocchi, A., & Gasbarrini, G. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90313-1 · Cited by 101
Self-citation
Cited by
Rezaie, A., Buresi, M., Lembo, A., Lin, H., McCallum, R., Rao, S., Schmulson, M., Valdovinos, M., Zakko, S., & Pimentel, M. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.46 · Cited by 852
Small intestinal bacterial overgrowth syndrome
Bures, J. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i24.2978 · Cited by 620
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00004 · Cited by 466
(2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.03951.x · Cited by 444
β Galactosidases and their potential applications: a review
Husain, Q. (2010) · Critical Reviews in Biotechnology · doi:10.3109/07388550903330497 · Cited by 420
Metadata
- Authors
- Stefano, D., Malservisi, Veneto, Ferrieri, & Corazza
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2000-05
- Volume
- 14
- Issue
- 5
- Pages
- 551-556
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2091756720
- Cited by
- 154
- References
- 1
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rifaximin versus chlortetracycline in the short‐term treatment of small intestinal bacterial overgrowth. https://app.cochat.ai/papers/10.1046/j.1365-2036.2000.00751.x
- The paper
- Stefano, D., Malservisi, Veneto, Ferrieri, & Corazza. (2000). Rifaximin versus chlortetracycline in the short‐term treatment of small intestinal bacterial overgrowth. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2000.00751.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.